Home / Health care / baseballnewssource : reported that Roth Capital Begins Coverage on Kite Pharma, Inc. (KITE)
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

baseballnewssource : reported that Roth Capital Begins Coverage on Kite Pharma, Inc. (KITE)

This content may collect you by Victoria Hunter

We will quote to you most important and trendy news about all kind of Therapy of the best health sites Like : “baseballnewssource” and the most famous medical experts : Chris Copeland

daily : 2017-01-12 & on time : 5:16

as declared in

Kite Pharma, Inc. (KITE) SVP Jeffrey Wiezorek Sells 1,500 Shares

Kite Pharma, Inc. (KITE) SVP Jeffrey Wiezorek Sells 1,500 Shares

image uploaded by “baseballnewssource” site

Kite Pharma, Inc. (NASDAQ:KITE) SVP Jeffrey Wiezorek sold 1,500 shares of Kite Pharma stock in a transaction dated Friday, January 6th.The shares were sold at an average price of $50.00, for a total transaction of $75,000.00.Following the completion of the transaction, the senior vice president now directly owns 22,195 shares of the company’s stock, valued at approximately $1,109,750.

about the details read more from here

Roth Capital Begins Coverage on Kite Pharma, Inc. (KITE)

Roth Capital Begins Coverage on Kite Pharma, Inc. (KITE)

image uploaded by “sportsperspectives” site

Roth Capital assumed coverage on shares of Kite Pharma, Inc. (NASDAQ:KITE) in a research note released on Wednesday.The firm issued a buy rating and a $68.00 price target on the biopharmaceutical company’s stock.Several other equities analysts also recently weighed in on the company.

about the details read more from here

Kite Pharma, Inc. (KITE) Upgraded to “Strong-Buy” by Zacks Investment Research

Kite Pharma, Inc. (KITE) Upgraded to “Strong-Buy” by Zacks Investment Research

image uploaded by “com-unik” site

Zacks Investment Research upgraded shares of Kite Pharma, Inc. (NASDAQ:KITE) from a hold rating to a strong-buy rating in a report published on Tuesday morning.They currently have $60.00 price objective on the biopharmaceutical company’s stock.According to Zacks, “Kite Pharma is focused on the development of immuno-oncology treatments and is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer.

about the details read more from here

Kite Pharma, Inc. (KITE) Research Coverage Started at Roth Capital

Kite Pharma, Inc. (KITE) Research Coverage Started at Roth Capital

image uploaded by “mareainformativa” site

Roth Capital initiated coverage on shares of Kite Pharma, Inc. (NASDAQ:KITE) in a report released on Wednesday morning.The brokerage issued a buy rating and a $68.00 price objective on the biopharmaceutical company’s stock.A number of other research firms also recently issued reports on KITE.

about the details read more from here

To follow all the new news about Therapy

About admin_health

Check Also

Spanish scientists develop New treatment method for Wilson disease by gene Therapy

Scientists at the Center for Applied Medical Research (CIMA) at the University of Navarra (Spain) …